1. Home
  2. OFS vs ACET Comparison

OFS vs ACET Comparison

Compare OFS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFS Capital Corporation

OFS

OFS Capital Corporation

HOLD

Current Price

$5.05

Market Cap

66.3M

Sector

Finance

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.56

Market Cap

93.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFS
ACET
Founded
2001
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.3M
93.5M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
OFS
ACET
Price
$5.05
$0.56
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
89.4K
1.8M
Earning Date
10-30-2025
11-05-2025
Dividend Yield
13.20%
N/A
EPS Growth
N/A
N/A
EPS
0.24
N/A
Revenue
$42,970,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.59
$0.45
52 Week High
$9.80
$1.13

Technical Indicators

Market Signals
Indicator
OFS
ACET
Relative Strength Index (RSI) 38.29 35.71
Support Level $4.69 $0.53
Resistance Level $5.10 $0.70
Average True Range (ATR) 0.22 0.06
MACD 0.10 0.00
Stochastic Oscillator 76.67 17.45

Price Performance

Historical Comparison
OFS
ACET

About OFS OFS Capital Corporation

OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: